专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070134262A1 Antigens encoded by alternative reading frames from pathogenic viruses 失效
标题翻译：由病原体病毒的替代阅读框编码的抗原
公开(公告)号：US20070134262A1
公开(公告)日：2007-06-14
申请号：US10512790
申请日：2003-07-24
申请人： Frank Mattner , Walter Schmidt , Andre Habel
发明人： Frank Mattner , Walter Schmidt , Andre Habel
IPC分类号： C12Q1/70 , A61K39/12 , A61K39/21 , A61K39/29 , C07K14/16
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/145 , A61K39/292 , A61K2039/525 , A61K2039/55516 , A61K2039/55561 , C07K2319/00 , C12N2760/16022 , C12N2760/16122 , C12N2760/16134 , C12N2770/24222 , C12N2770/24234 , Y02A50/464
摘要： The invention discloses polypeptides encoded by an alternative reading frame of a pathogenic virus, which polypeptides—start with a methionine amino acid residue,—comprise an antigenic determinant and—comprise more than 7 amino acid residues and fragments of said polypeptides comprising more than 7 amino acids.
摘要翻译：本发明公开了由病毒性病毒的替代阅读框编码的多肽，该多肽由甲硫氨酸氨基酸残基开始， - 确定抗原决定簇，并且包含多于7个氨基酸的残基，所述多肽的片段包含多于7个氨基酸酸。

2. 发明授权

US07528223B2 Antigens encoded by alternative reading frames from pathogenic viruses 失效
标题翻译：由病原体病毒的替代阅读框编码的抗原
公开(公告)号：US07528223B2
公开(公告)日：2009-05-05
申请号：US10512790
申请日：2003-07-24
申请人： Frank Mattner , Walter Schmidt , Andre Habel
发明人： Frank Mattner , Walter Schmidt , Andre Habel
IPC分类号： C07K5/00 , A61K39/145 , A61K39/00
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/145 , A61K39/292 , A61K2039/525 , A61K2039/55516 , A61K2039/55561 , C07K2319/00 , C12N2760/16022 , C12N2760/16122 , C12N2760/16134 , C12N2770/24222 , C12N2770/24234 , Y02A50/464
摘要： The invention discloses polypeptides encoded by an alternative reading frame of a pathogenic virus, which polypeptides—start with a methionine amino acid residue,—comprise an antigenic determinant and—comprise more than 7 amino acid residues and fragments of said polypeptides comprising more than 7 amino acids.
摘要翻译：本发明公开了由病毒性病毒的替代阅读框编码的多肽，该多肽由甲硫氨酸氨基酸残基开始， - 确定抗原决定簇，并且包含多于7个氨基酸的残基，所述多肽的片段包含多于7个氨基酸酸。

3. 发明申请

US20090081246A1 METHOD FOR ISOLATING HEPATITIS C VIRUS PEPTIDES 审中-公开
标题翻译：用于分离HEPATITIS C病毒肽的方法
公开(公告)号：US20090081246A1
公开(公告)日：2009-03-26
申请号：US12112758
申请日：2008-04-30
申请人： Michael Buschle , Andre Habel , Christoph Klade , Frank Mattner , Oleksandr Otava , Oresta Vytvytska , Wolfgang Zauner , Sandra Zinke , Helen Kirlappos
发明人： Michael Buschle , Andre Habel , Christoph Klade , Frank Mattner , Oleksandr Otava , Oresta Vytvytska , Wolfgang Zauner , Sandra Zinke , Helen Kirlappos
IPC分类号： A61K39/00 , C12N5/00 , A61K35/12
CPC分类号： C07K7/06 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/292 , A61K2039/525 , A61K2039/57 , C07K7/08 , C07K14/005 , C07K2319/00 , C12N2710/16122 , C12N2760/16122 , C12N2770/24222 , C12N2770/24234 , G01N2500/04 , Y10S930/223
摘要： Described are methods for isolating Hepatitis C Virus peptides (HPs) that have a binding capacity to a MHC/HLA molecule or a complex comprising the HCV-peptide and the MHC/HLA molecule. In one aspect, these methods include providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterizing the HCV-peptide from said complex. Also described are immunogenic compositions that stimulate a specific T cell response to hepatitis C virus when administered to a subject in an effective amount.
摘要翻译：描述了分离具有对MHC / HLA分子的结合能力的丙型肝炎病毒肽（HP）或包含HCV-肽和MHC / HLA分子的复合物的方法。一方面，这些方法包括提供一组HCV肽，所述池含有与所述MHC / HLA分子结合的HCV-肽和不结合所述MHC / HLA分子的HCV-肽，所述MHC / HLA分子与所述HCV-肽库相结合，由此形成具有与所述MHC / HLA分子的结合能力的HCV肽与所述MHC / HLA分子结合，形成包含所述HCV-肽和所述MHC / HLA分子的复合物，检测和任选地将所述复合物与不结合所述MHC / HLA分子的HCV-肽分离，并任选从所述复合物中分离和表征HCV-肽。还描述了当以有效量施用于受试者时刺激特异性T细胞对丙型肝炎病毒的响应的免疫原性组合物。

4. 发明申请

US20060216691A1 Method for isolating hepatitis c virus peptides 失效
标题翻译：分离丙型肝炎病毒肽的方法
公开(公告)号：US20060216691A1
公开(公告)日：2006-09-28
申请号：US10512885
申请日：2003-08-27
申请人： Michael Buschle , Andre Habel , Christoph Klade , Frank Mattner , Oleksandr Otava , Oresta Vytvytska , Wolfgang Zauner , Sandra Zinke , Helen Kirlappos
发明人： Michael Buschle , Andre Habel , Christoph Klade , Frank Mattner , Oleksandr Otava , Oresta Vytvytska , Wolfgang Zauner , Sandra Zinke , Helen Kirlappos
IPC分类号： C12Q1/70 , C07K14/18
CPC分类号： C07K7/06 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/292 , A61K2039/525 , A61K2039/57 , C07K7/08 , C07K14/005 , C07K2319/00 , C12N2710/16122 , C12N2760/16122 , C12N2770/24222 , C12N2770/24234 , G01N2500/04 , Y10S930/223
摘要： Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: —providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, —contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, —detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterising the HCV-peptide from said complex.
摘要翻译：描述了分离具有与MHC / HLA分子的结合能力的丙型肝炎病毒肽（HP）或包含所述HCV-肽和所述MHC / HLA分子的复合物的方法，其特征在于以下步骤： - 提供HCV池肽，所述池包含结合所述MHC / HLA分子的HCV-肽和不结合所述MHC / HLA分子的HCV-肽， - 用所述HCV-肽池接触所述MHC / HLA分子，由此HCV- 具有与所述MHC / HLA分子的结合能力的肽与所述MHC / HLA分子结合，形成包含所述HCV-肽和所述MHC / HLA分子的复合物， - 检测并任选地将所述复合物与所述HCV-肽分离不结合所述MHC / HLA分子并任选地从所述复合物中分离和表征HCV-肽。

5. 发明授权

US07378234B2 Method for isolating hepatitis C virus peptides 失效
标题翻译：分离丙型肝炎病毒肽的方法
公开(公告)号：US07378234B2
公开(公告)日：2008-05-27
申请号：US10512885
申请日：2003-08-27
申请人： Michael Buschle , Andre Habel , Christoph Klade , Frank Mattner , Alexander Otava , Oresta Vytvytska , Wolfgang Zauner , Sandra Zinke , Helen Kirlappos
发明人： Michael Buschle , Andre Habel , Christoph Klade , Frank Mattner , Alexander Otava , Oresta Vytvytska , Wolfgang Zauner , Sandra Zinke , Helen Kirlappos
IPC分类号： A61K39/00 , A61K51/00 , A61K39/12 , A61K39/29 , C12Q1/70
CPC分类号： C07K7/06 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/292 , A61K2039/525 , A61K2039/57 , C07K7/08 , C07K14/005 , C07K2319/00 , C12N2710/16122 , C12N2760/16122 , C12N2770/24222 , C12N2770/24234 , G01N2500/04 , Y10S930/223
摘要： Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: —providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, —contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, —detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterizing the HCV-peptide from said complex.
摘要翻译：描述了分离具有与MHC / HLA分子的结合能力的丙型肝炎病毒肽（HP）或包含所述HCV-肽和所述MHC / HLA分子的复合物的方法，其特征在于以下步骤： - 提供HCV池肽，所述池包含结合所述MHC / HLA分子的HCV-肽和不结合所述MHC / HLA分子的HCV-肽， - 用所述HCV-肽池接触所述MHC / HLA分子，由此HCV- 具有与所述MHC / HLA分子的结合能力的肽与所述MHC / HLA分子结合，形成包含所述HCV-肽和所述MHC / HLA分子的复合物， - 检测并任选地将所述复合物与所述HCV-肽分离不结合所述MHC / HLA分子并任选地从所述复合物中分离和表征HCV-肽。

6. 发明授权

US08618046B2 Treatment of atherosclerosis with cholesterol ester transport protein mimotopes 失效
标题翻译：用胆固醇酯转运蛋白模拟表位治疗动脉粥样硬化
公开(公告)号：US08618046B2
公开(公告)日：2013-12-31
申请号：US12673081
申请日：2008-08-08
申请人： Sylvia Brunner , Petra Luehrs , Frank Mattner , Walter Schmidt , Barbara Wittmann
发明人： Sylvia Brunner , Petra Luehrs , Frank Mattner , Walter Schmidt , Barbara Wittmann
IPC分类号： A61K38/10 , A61K38/04 , A61P9/10 , C07K7/08
CPC分类号： C07K7/08 , A61K38/1709 , A61K39/0012 , A61K47/48284 , A61K47/643 , A61K47/646 , A61K2039/55505 , A61K2039/55555 , A61K2039/55566 , A61K2039/6081 , C07K7/06 , C07K16/18
摘要： The present invention relates to a method for treating atherosclerosis and/or atherosclerosis sequelae with a compound that includes FX8(F)oPX9HX10X11X12DX2X3X4X5X6X7 where X8 is G, A, F, Y or K, X9 is E, Y, A, Q, K or S, X10 is H, V, L, F or I, X11 is L, W, S, I, F or Y, X12 is V, T, F or I, X5 is S or Y, X6 is L, A or I, X7 is S, N or T, and o is 0 or 1.
摘要翻译：本发明涉及一种用包含FX8（F）oPX9HX10X11X12DX2X3X4X5X6X7的化合物治疗动脉粥样硬化和/或动脉粥样硬化后遗症的方法，其中X8是G，A，F，Y或K，X9是E，Y，A，Q，K或 S，X10为H，V，L，F或I，X11为L，W，S，I，F或Y，X12为V，T，F或I，X5为S或Y，X6为L， I，X7为S，N或T，o为0或1。

7. 发明申请

US20130287807A1 COMPOUNDS FOR TREATING SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE 审中-公开
标题翻译：用于治疗与帕金森病相关的症状的化合物
公开(公告)号：US20130287807A1
公开(公告)日：2013-10-31
申请号：US13770594
申请日：2013-02-19
申请人： Markus MANDLER , Frank Mattner , Walter Schmidt
发明人： Markus MANDLER , Frank Mattner , Walter Schmidt
IPC分类号： C07K7/06 , A61K39/00
CPC分类号： A61K39/00 , A61K38/08 , C07K7/06 , C07K16/18 , C07K2317/34
摘要： The present invention relates to a compound comprising a peptide for treating, preventing and/or ameliorating motor symptoms of Parkinson's disease, said peptide having a binding capacity to an antibody which is specific for an epitope of the amyloid-beta-peptide (Aβ).
摘要翻译：本发明涉及一种包含用于治疗，预防和/或改善帕金森病运动症状的肽的化合物，所述肽具有对淀粉样蛋白-β-肽（Abeta）表位特异的抗体的结合能力。

8. 发明授权

US08022180B2 Method for preventing and treating Alzheimer's disease 失效
标题翻译：预防和治疗阿尔茨海默病的方法
公开(公告)号：US08022180B2
公开(公告)日：2011-09-20
申请号：US11630679
申请日：2005-07-06
申请人： Frank Mattner , Walter Schmidt
发明人： Frank Mattner , Walter Schmidt
IPC分类号： A61K38/00 , A61K38/04 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00
CPC分类号： G01N33/6896 , A61K39/0007 , G01N2800/2821
摘要： The invention relates to the use of a compound comprising the following amino acid sequence X1X2X3X4X5X6X7, wherein X1 is an amino acid, except of C, X2 is an amino acid, except of C, X3 is an amino acid, except of C, X4 is an amino acid, except of C, X5 is an amino acid, except of C, X6 is not present or any amino acid, X7 is not present or any amino acid, and wherein X1X2X3X4X5X6 is not DAEFRH, said compound having a binding capacity to an antibody being specific for the natural N-terminal Aβ42 sequence DAEFRH, and 5-mers thereof having a binding capacity to said antibody being specific for the natural N-terminal Aβ42 sequence DAEFRH, for the preparation of a vaccine for Alzheimer's disease.
摘要翻译：本发明涉及以下氨基酸序列X1X2X3X4X5X6X7的化合物，其中X1为氨基酸，C除外，X2为氨基酸，C除外，X为氨基酸，C为X，X 4为氨基酸除C以外，X5为氨基酸，C为X6，不存在X6，不存在任何氨基酸X7或氨基酸，X1X2X3X4X5X6不为DAEFRH，所述化合物的结合能力为对于天然N-末端A末端A和Bgr 42序列DAEFRH具有特异性的抗体，其具有对所述抗体具有结合能力的5-序列，其对于天然N末端A和Bgr 42序列DAEFRH是特异性的，用于制备阿尔茨海默病疾病。

9. 发明申请

US20090004210A1 Method for Preventing and Treating Alzheimer's Disease 失效
标题翻译：预防和治疗阿尔茨海默病的方法
公开(公告)号：US20090004210A1
公开(公告)日：2009-01-01
申请号：US11630679
申请日：2005-07-06
申请人： Frank Mattner , Walter Schmidt
发明人： Frank Mattner , Walter Schmidt
IPC分类号： A61K39/00 , C07K7/06 , C07K4/00 , A61K38/08 , C40B30/04
CPC分类号： G01N33/6896 , A61K39/0007 , G01N2800/2821
摘要： The invention relates to the use of a compound comprising the following amino acid sequence X1X2X3X4X5X6X7, wherein X1 is an amino acid, except of C, X2 is an amino acid, except of C, X3 is an amino acid, except of C, X4 is an amino acid, except of C, X5 is an amino acid, except of C, X6 is not present or any amino acid, X7 is not present or any amino acid, and wherein X1X2X3X4X5X6 is not DAEFRH, said compound having a binding capacity to an antibody being specific for the natural N-terminal Aβ42 sequence DAEFRH, and 5-mers thereof having a binding capacity to said antibody being specific for the natural N-terminal Aβ42 sequence DAEFRH, for the preparation of a vaccine for Alzheimer's disease.
摘要翻译：本发明涉及以下氨基酸序列X1X2X3X4X5X6X7的化合物，其中X1为氨基酸，C除外，X2为氨基酸，C除外，X为氨基酸，C为X，X 4为氨基酸除C以外，X5为氨基酸，C为X6，不存在X6，不存在任何氨基酸X7或氨基酸，X1X2X3X4X5X6不为DAEFRH，所述化合物的结合能力为针对天然N末端Abeta42序列DAEFRH特异的抗体及其对所述抗体的结合能力的5聚体对于天然N末端Aβ42序列DAEFRH是特异性的，用于制备阿尔茨海默氏病疫苗。

10. 发明申请

US20120269836A1 Vaccine 有权
标题翻译：疫苗
公开(公告)号：US20120269836A1
公开(公告)日：2012-10-25
申请号：US13386603
申请日：2010-07-23
申请人： Günther Staffler , Petra Lührs , Andreas Mairhofer , Frank Mattner , Walter Schmidt , Andrea Dolischka
发明人： Günther Staffler , Petra Lührs , Andreas Mairhofer , Frank Mattner , Walter Schmidt , Andrea Dolischka
IPC分类号： A61K39/00 , A61P9/12 , A61P27/02 , A61P13/12 , A61P9/00 , A61P37/04 , A61P9/10
CPC分类号： A61K39/385 , A61K39/0008 , A61K2039/55505 , A61K2039/6037 , A61K2039/6081 , C07K14/435
摘要： Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula I) (SEQ ID NO: 1) (X1)m(X2)n(X3)oX4X5HPX6, for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).
摘要翻译：包含与药学上可接受的载体结合的肽的疫苗，所述肽具有氨基酸序列（式I）（SEQ ID NO：1）（X1）m（X2）n（X3）oX4X5HPX6，用于治疗和/或预防物理与肾素激活的血管紧张素系统相关的疾病，其中X1是G或D，X2是A，P，M，G或R，X3是G，A，H或V，X4是S，A，D或 Y，X5为A，D，H，S，N或I，X6为A，L或F，其中m，n和o分别为0或1，前提是当o为0，n为0时，当n为0时为0，并且其中肽不是DRVYIHPF（SEQ ID NO：4）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式